Evaluation of commercial assays for the assessment of SARS-CoV-2 antibody response in hemodialysis patients

Di Meo, Ashley; Ma, Liyan; Yau, Kevin; Abe, Kento T.; Colwill, Karen; Gingras, Anne-Claude; Kozak, Robert; Hladunewich, Michelle A.; Yip, Paul M.

doi:10.1016/j.clinbiochem.2023.110681

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum was collected from participants at the end of the acute phase of illness (day 14) and during the convalescent phase, (greater than 3 months after diagnosis) which is associated with long COVID (day > 90). Serum underwent analysis to quantify anti-Spike and anti-Nucleocapsid IgG titers using the Roche Elecsys immunoassay, using previously described methods [ 15 ].…”

Section: Methodsmentioning

confidence: 99%

Differential Gene Expression in the Upper Respiratory Tract following Acute COVID-19 Infection in Ambulatory Patients That Develop Long COVID

Biondi,

Addo,

Zahoor

et al. 2024

Pathogens

Self Cite

View full text Add to dashboard Cite

Background: Post-acute sequelae of COVID-19, or long COVID, is a condition characterized by persistent COVID-19 symptoms. As long COVID is defined by clinical criteria after an elapsed period, an opportunity for early intervention may aid in future prophylactic approaches; however, at present, the pathobiological mechanisms are multifactorial. By analyzing early virally infected upper respiratory tract tissue prior to eventual clinical diagnosis, it may be possible to identify biomarkers of altered immune response to facilitate future studies and interventions. Methods: This is a sub-group analysis of samples collected from those with confirmed COVID-19. RNA extraction from nasopharyngeal/mid-turbinate samples, sequencing, and bioinformatic analysis were performed to analyze long COVID and non-long COVID cohorts at day 14 post infection. Differences in mean viral load at various timepoints were analyzed as well as serological data. Results: We identified 26 upregulated genes in patients experiencing long COVID. Dysregulated pathways including complement and fibrinolysis pathways and IL-7 upregulation. Additionally, genes involved in neurotransmission were dysregulated, and the long COVID group had a significantly higher viral load and slower viral clearance. Conclusions: Uncovering early gene pathway abnormalities associated with eventual long COVID diagnosis may aid in early identification. We show that, post acute infection, in situ pathogenic deviations in viral response are associated with patients destined to meet consensus long COVID diagnosis that is entirely dependent on clinical factors. These results identify an important biological temporal window in the natural history of COVID-19 infection and long COVID pathogenesis amenable to testing from standard-of-care upper respiratory tract specimens.

show abstract

Section: Methodsmentioning

confidence: 99%